Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

IMS: China Pharma Revenues to Total $155-$185 Billion in 2018

publication date: Dec 1, 2014
According to a new IMS Health report, China is already the world's second largest pharmaceutical market, and it will spend between $155 billion and $185 billion on drugs in 2018. IMS says China's citizens will expect more and better healthcare, raising revenues, but the government will apply pressure on costs, restraining overall spending levels. In addition, the health consultancy believes drug spending in 21 "pharmerging" countries will rise 50% by 2018 over 2013 levels. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital